Beginner's Guide to Growth Hormone Peptides: GHRH, GHRP, and Secretagogues in Research

Overview

Growth hormone (GH) peptides are among the most studied compounds in peptide research. This guide introduces the key classes of GH-related peptides, explains the underlying physiology, and summarizes published research findings for each major compound. It is intended as an entry point for researchers new to this area.

The Growth Hormone Axis

Growth hormone release is regulated by two primary hypothalamic signals:

1. GHRH (Growth Hormone-Releasing Hormone): Stimulates GH release from pituitary somatotrophs
2. Somatostatin: Inhibits GH release (acts as a brake)

GH is released in pulses, primarily during sleep and in response to exercise, fasting, and stress. It acts on the liver to produce IGF-1 (insulin-like growth factor 1), which mediates many of GH's anabolic and metabolic effects.

Research peptides in this space work by either mimicking GHRH, mimicking ghrelin (which also stimulates GH release), or doing both simultaneously.

Class 1: GHRH Analogues

Sermorelin

Sermorelin is a synthetic analogue of the first 29 amino acids of GHRH. It was FDA-approved as a diagnostic agent for GH deficiency and as a treatment for GH deficiency in children (Geref, withdrawn from market in 2008 for commercial reasons, not safety).

Sermorelin has a short half-life (~10–20 minutes) due to rapid enzymatic cleavage at the N-terminus by dipeptidyl peptidase IV (DPP-IV).

Key research: Walker et al. (1990) demonstrated that sermorelin administration restored GH pulsatility in GH-deficient adults [1].

CJC-1295

CJC-1295 is a modified GHRH analogue with a Drug Affinity Complex (DAC) modification that allows it to bind albumin, dramatically extending its half-life to 6–8 days. This enables less frequent dosing compared to sermorelin.

Without DAC (sometimes called "CJC-1295 without DAC" or "Mod GRF 1-29"), the half-life is approximately 30 minutes.

Key research: Teichman et al. (2006) demonstrated that CJC-1295 with DAC produced sustained increases in GH and IGF-1 levels over 6 days in healthy adults [2].

Class 2: GHRPs (Growth Hormone-Releasing Peptides)

GHRPs work through a different receptor — the ghrelin receptor (GHSR-1a) — rather than the GHRH receptor. They stimulate GH release through a complementary pathway, and when combined with GHRH analogues, produce synergistic GH release.

GHRP-6

GHRP-6 was one of the first synthetic GH secretagogues studied. It is a hexapeptide that potently stimulates GH release but also significantly increases appetite and cortisol — effects mediated by ghrelin receptor activation in the hypothalamus and adrenal glands.

GHRP-2

GHRP-2 is more potent than GHRP-6 with a stronger GH release signal, but also produces more pronounced cortisol and prolactin elevation.

Ipamorelin

Ipamorelin is a third-generation GHRP with high selectivity for the ghrelin receptor. Unlike GHRP-6 and GHRP-2, it produces minimal cortisol, prolactin, or appetite stimulation at research doses — making it the most selective GHRP studied to date.

Key research: Raun et al. (1998) demonstrated that ipamorelin produced GH release comparable to GHRP-6 with significantly less cortisol and ACTH stimulation in animal models [3].

Class 3: Synthetic Secretagogues

MK-677 (Ibutamoren)

MK-677 is a non-peptide ghrelin mimetic that orally activates the GHRH receptor. It is not a peptide but is often grouped with GH peptides due to its mechanism. It has a long half-life (~24 hours) and produces sustained GH and IGF-1 elevation.

Key research: Murphy et al. (1998) demonstrated that MK-677 increased GH and IGF-1 in elderly subjects and improved lean body mass [4].

Synergy: GHRH + GHRP

One of the most consistent findings in GH peptide research is the synergistic GH release when a GHRH analogue is combined with a GHRP. The two classes act on different receptors and through different intracellular pathways, producing GH release that is significantly greater than either compound alone.

Bowers et al. (1990) first demonstrated this synergy, showing that GHRH + GHRP-6 co-administration produced GH release 5–10x greater than either alone [5].

This is the mechanistic basis for the commonly studied CJC-1295 + Ipamorelin combination in research settings.

Summary Table

| Compound | Class | Receptor | Half-Life | Notable Property | |---|---|---|---|---| | Sermorelin | GHRH analogue | GHRH-R | ~10–20 min | FDA history; short-acting | | CJC-1295 (DAC) | GHRH analogue | GHRH-R | 6–8 days | Long-acting via albumin binding | | GHRP-6 | GHRP | GHSR-1a | ~15–60 min | Appetite stimulation | | GHRP-2 | GHRP | GHSR-1a | ~15–60 min | Potent; cortisol elevation | | Ipamorelin | GHRP | GHSR-1a | ~2 hours | Selective; minimal side effects | | MK-677 | Secretagogue | GHSR-1a | ~24 hours | Oral; non-peptide |

References

1. Walker, R.F., et al. (1990). Pulsatile growth hormone secretion in old rats: restoration by continuous infusion of growth hormone-releasing hormone. Neuroendocrinology, 51(5), 551–555.
2. Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
3. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
4. Murphy, M.G., et al. (1998). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research, 13(7), 1102–1111.
5. Bowers, C.Y., et al. (1990). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537–1545.